EUCTR2022-002593-89-BG招募中1 期
A Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy Safety, and Tolerability ofTEV-48574 in Adult Patients with Moderate to Severe Ulcerative Colitis or Crohn's Disease who completed the treatment phase of the Dose-Ranging Study - RELIEVE UCCD LTE
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 218
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1.Maintenance Period: a. Adults of male and female sex (without restrictions on gender) who at the time of informed consent achieved clinical response and/or clinical remission at week 14 of TV48574-IMM-20036 (the 14-week of DRF study) or in the re-induction period of this study.
- •OLE Period: Adults of male and female sex (without restrictions based on gender) who have clinical response and/or clinical remission at week 44 of the maintenance period of this study.
- •- Clinical response assessed by decrease from DRF study baseline in
- •modified (9-point rectal bleeding, stool frequency, and endoscopy) Mayo score by =2 points and at least 30%, with a decrease in rectal bleeding subscore of =1 point or an absolute subscore of 0 or 1 at week 14 of the of the DRF study/re-induction period or week 44 of the maintenance period in patients with moderate to severe UC .
- •- Clinical remission at week 14 of the DRF study/re-induction period or week 44 of the maintenance period in patients with moderate to severe UC. Clinical remission is a modified (9- point rectal bleeding, stool frequency, and endoscopy) Mayo score of =2 points, which is defined by:
- •stool frequency subscore of 0 or 1,
- •rectal bleeding subscore of 0, and
- •endoscopic subscore of 0 or 1, where a score of 1 does not include
- •- Clinical response assessed by =100-point decrease CDAI score from
- •DRF study baseline week 14 of the TV48574-IMM-20036 DRF study/reinduction period or week 44 of the maintenance period in patients with moderate to severe CD
- •- Clinical remission defined as a CDAI score <150 at week 14 of the DRF study/re-induction period or week 44 of the maintenance period in patients with moderate to severe CD
- •2. Re-induction period: Adults of male and female sex (without restrictions
- •based on gender) who did not achieve clinical response and/or clinical remission at week 14 of the TV48574 IMM 20036 DRF study
- •b. Patients who are women of childbearing potential (WOCBP) should have a negative ß- human chorionic gonadotropin test result and practice a highly effective method of birth control.
- •Male patients (including vasectomized) with WOCBP partners should use condoms after the first IMP administration and throughout the study
- •c. The patient must be willing and able to comply with study restrictions and to remain at the investigational center for the required duration during the study period, and willing to return to the investigational center for further visits, as applicable, and the follow-up procedures and assessments as specified in this protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 156
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 62
排除标准
- •a. Patients who discontinued the TV48574-IMM-20036 DRF study before scheduled week 14 visit (any reason including lack of efficacy, safety, or personal reasons) and patients who didn’t meet the definition of clinical response or clinical remission based on their DRF week 14 assessment b. The patient has any concomitant conditions or treatments that could interfere with study conduct, influence the interpretation of study observations/results, or put the patient at increased risk during the study as judged by the investigator and/or the clinical study physician. c. Diagnosis of indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, or microscopic colitis. d. Patient has colonic dysplasia or neoplasia with exception of dysplasia on a completely excised adenomatous polyp [not a sessile one]), toxic megacolon, primary sclerosing cholangitis, known non-passable colonic stricture, presence of colonic or small bowel stoma, presence of non-passable colonic or small bowel obstruction or resection preventing the endoscopy procedure, or fulminant colitis. e. Presence of active enteric infections (positive stool culture) or a history of serious infection (requiring parenteral antibiotic and/or hospitalization) within 4 weeks prior to the first study visit. f. Patient anticipates requiring major surgery during this study. g. A history of an opportunistic infection (eg, CMV, cytomegalovirus retinitis, Pneumocystis carinii, or aspergillosis). h. A history of more than 2 herpes zoster episodes in the last 5 years or multimetameric herpes zoster. i. A history of or ongoing chronic or recurrent serious infectious disease (eg, infected indwelling prosthesis or osteomyelitis). j. Current or history of chronic liver or biliary disease (with the exception of Gilbert' syndrome, asymptomatic gallstones or uncomplicated fatty liver disease) at screening or (baseline ALT) (or AST >2× ULN) or bilirubin >1.5x ULN (isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%) at week 14 of the DRF study or the re-induction period. k. Absolute neutrophil count <1.5x109/L or Hemoglobin <8 g/dL or
- •lymphocyte count <0.8x109/L or platelet count <75,000/mL at week
- •14 of the DRF study or the re-induction period. If a subject fails to meet an exclusion laboratory criterion due to an isolated laboratory test falling outside of the normal acceptable range, a single retest will be permitted once, with the retest value determining subject eligibility for the study. l. The patient has QTcF>480 ms at week 14 of the DRF study or the reinduction period. If a subject fails to meet an exclusion criterion due to an isolated electrocardiogram (ECG) reading falling outside of the normal acceptable range, a single retest will be permitted once, with the retest determining subject eligibility for the study. m. Any acute infection that in the opinion of the investigator compromises the safety of the patients . n. The patient is currently pregnant or lactating or is planning to become pregnant or to lactate during the study or for at least 50 days after administration of the last dose of IMP in case of early termination. Any woman becoming pregnant during the study will be withdrawn from the study. o. The patient has a known hypersensitivity to the IMP and/or
- •excipients. p. Presence of a transplanted organ. q. A history of malignancy within the last 5 years(exception: basal cell carcinoma or in situ ca
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's DiseaseModerate to severe Ulcerative colitis or moderate to severe Crohn'sdiseaseMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.0Level: LLTClassification code 10011400Term: Crohn's colitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2022-002593-89-CZTeva Branded Pharmaceutical Products R&D, Inc.218
招募中
1 期
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's DiseaseEUCTR2022-002593-89-SKTeva Branded Pharmaceutical Products R&D, Inc.218
尚未招募
2 期
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's DiseaseJPRN-jRCT2061230004Yamasaki Fumie11
招募中
2 期
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s DiseaseUlcerative colitis2024-515027-11-00Teva Branded Pharmaceutical Products R&D LLC187
招募中
1 期
A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of PTC518 in Participants With Huntington’s DiseaseHuntington's DiseaseMedDRA version: 20.0Level: PTClassification code: 10070668Term: Huntington's disease Class: 100000004850CTIS2023-504628-24-00PTC Therapeutics Inc.358